Problems › Costs Are Rising Faster Than Prices › Healthcare Providers
A cost squeeze under value-based contracts is a risk allocation problem as much as a reimbursement one. Healthcare providers carry a specific bind here — downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. Until that is priced, cost per episode will keep moving for reasons nobody can attribute, and the debate about input cost pass-through will stay a matter of opinion.
A cost squeeze under value-based contracts is a risk allocation problem as much as a reimbursement one. Healthcare providers carry a specific bind here — downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. Until that is priced, cost per episode will keep moving for reasons nobody can attribute, and the debate about input cost pass-through will stay a matter of opinion.
When cost per episode rises faster than revenue per attributed life, the immediate reflex is to reduce utilization or tighten internal protocols. It is worth doing and it is finite: you can only remove cost once inside an episode, while the downside risk on the 38,000 attributed lives continues.
The durable responses are structural. Reopen value-based contracts to tie payment updates to a published medical-cost index rather than to annual negotiation. Shorten contract terms so repricing occurs at renewal. Shift the composition of the panel so that contribution per provider improves on the subset of payers where cost per episode can be passed through without repeated approval.
The other half is payer mix. In most panels the squeeze is not uniform—some contracts allow cost pass-through and some do not—and moving attributed lives toward the first group is usually faster than winning a price argument inside the second.
These three together are the signature. One on its own usually points somewhere else.
✓ Cost per episode is rising while the number of attributed lives under value-based contracts holds steady
✓ Every material change in reimbursement requires a fresh negotiation with the payer
✓ Value-based contracts contain no escalation mechanism tied to external cost indices
The move that usually makes it worse. Absorbing higher cost per episode to protect panel size, which trains payers to expect absorption and makes the eventual correction larger.
It is for you if you run or finance a healthcare provider and gross margin is falling while volumes hold. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a healthcare provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Turn $6.8 M downside-risk liability into a $22–35 M licensing platform within 36 months.
The leak it closes. Eliminates $6.8 M downside exposure by enabling proactive utilization management.
The assumption it rests on. Cost-measurement platform achieves <5 % variance versus manual abstraction within 12 months — the engine put the probability at 0.75.
| Investment required | $2.1–3.5 M over 36 months |
| Expected return | 6.3–16.7× cash-on-cash within 36 months based on $196 M current revenue base. |
| Revenue, year 1 | $0 licensing revenue; $1.8 M internal cost avoidance |
| Revenue, year 2 | $4.2 M licensing ARR (40 physicians × $120K + 5 external practices × $400K) |
| Revenue, year 3 | $13.5 M licensing ARR (90 physicians × $120K + 18 external practices × $400K) plus $4–8 M shared-savings upside |
| Exit criteria | Terminate platform investment if variance exceeds 8 % by Month 18 OR if fewer than 40 physicians sign licensing agreements by Month 24; redeploy remaining capital to ASC surgeon-retention track. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Cost & Margin Improvement, one of 29 engagements the platform runs. For healthcare providers it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
Tie them to something external and verifiable, and give notice. A rise attributed to a published index is a fact; the same rise attributed to your costs is an invitation to negotiate.
Where a credible index exists, it removes the annual argument and usually pays for itself in the first cycle. The work is choosing an index the customer accepts as neutral.
Then the lever is at renewal, and the interim work is mix and cost to serve. It is also the moment to fix the contract, because the same squeeze will happen again.
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית